Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present VistaGen Therapeutics, Inc. (NASDAQ: VTGN).

Full DD Report for VTGN

You must become a subscriber to view this report.


Recent News from (NASDAQ: VTGN)

Premarket Gainers as of 9:15 am (9/13/2018)
PI   +39%  on Q2 earnings . More news on: Impinj, Inc., Geron Corporation, GNC Holdings, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: September, 13 2018 09:27
VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate from Pherin Pharmaceuticals for As-Needed Treatment of Social Anxiety Disorder
Phase 3-ready asset expands VistaGen’s CNS pipeline and complements its neuropsychiatry focus on Major Depressive Disorder (MDD) with AV-101   Novel PH94B nasal spray expected to enter pivotal Phase 3 development for as-needed (PRN) treatment of Social Anxiety Disorder (SAD...
Source: GlobeNewswire
Date: September, 13 2018 08:30
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating VistaGen Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK , Sept. 6, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of VistaGen Therapeutics, Inc. (NASDAQ: VTGN)...
Source: PR Newswire
Date: September, 06 2018 06:57

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-141.611.611.6751.571113,050
2018-12-131.701.621.701.616271,127
2018-12-121.721.701.721.6987,644
2018-12-111.761.721.7651.7077,823
2018-12-101.761.741.791.728664,415

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-147,49443,11817.3802Cover
2018-12-138,90037,33523.8382Cover
2018-12-128,79848,38718.1826Cover
2018-12-1110,15237,12627.3447Cover
2018-12-104,30431,23313.7803Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on VTGN.


About VistaGen Therapeutics, Inc. (NASDAQ: VTGN)

Logo for VistaGen Therapeutics, Inc. (NASDAQ: VTGN)

VistaGen Therapeutics, Inc. is a clinical stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system CNS . VistaGen s lead product candidate, AV , is a next generation, orally available prodrug candidate in Phase development, initially for the adjunctive treatment of Major Depressive Disorder MDD in patients with an inadequate response to standard antidepressants. AV s mechanism of action, as an N methyl D aspartate receptor NMDAR antagonist binding selectively at the glycine binding GlyB co agonist site of the NMDAR, is fundamentally differentiated from all antidepressants, as well as all atypical antipsychotics used adjunctively with standard antidepressants, currently approved by the U.S. Food and Drug Administration FDA . VistaGen s ongoing Phase a clinical study of AV in subjects with treatment resistant MDD is being conducted and funded by the U.S. National Institutes of Mental Health NIMH under its February Cooperative Research and Development Agreement CRADA with the NIMH. This NIMH sponsored Phase a study was initiated in October and is ongoing. The Principal Investigator of the study is Dr. Carlos Zarate, Jr., Chief of the NIMH s Experimental Therapeutics amp Pathophysiology Branch and its Section on Neurobiology and Treatment of Mood and Anxiety Disorders. Previous NIMH studies, including studies conducted by Dr. Zarate, have focused on the effects of intravenous I.V. ketamine on depression. These NIMH studies, as well as clinical research by others, have demonstrated robust antidepressant effects in patients with treatment resistant MDD within hours of a single low dose of I.V. ketamine and stimulated research and development around a new generation of antidepressants with potential to deliver ketamine like fast onset benefits without its side effects. Currently, VistaGen is preparing to launch a Phase b clinical study of AV for the adjunctive treatment of MDD in patients with an inadequate response to standard antidepressants. VistaGen anticipates commencement of this potentially pivotal, multi center, multi dose, double blind, placebo controlled Phase b efficacy and safety study in the fourth quarter of . Dr. Maurizio Fava, Professor of Psychiatry at Harvard Medical School and Director, Division of Clinical Research, Massachusetts General Hospital MGH Research Institute and Executive Director, MGH Clinical Trials Network and Institute, will be the Principal Investigator of this Phase b study. VistaGen also believes AV has broad therapeutic utility with multiple near term CNS pipeline expansion opportunities, including chronic neuropathic pain, epilepsy, Huntington s disease and Parkinson s disease. VistaGen is also focused on potential commercial applications of its human pluripotent stem cell hPSC technology platform, including drug rescue to develop proprietary new chemical entities NCEs for its internal drug candidate pipeline, and, through potential strategic collaborations, regenerative medicine RM using blood, cartilage, heart and liver cells derived from its hPSC technology.

 

Contact Information

 

 

Current Management

  • Shawn K. Singh / CEO
  • H. Ralph Snodgrass / President, CSO, CoFounder
  • Jerrold D. Dotson / CFO, Corporate Secretary
  • Caren Scannell / Associate
  • Jon S. Saxe / Chairman
  • Shawn K. Singh /
  • H. Ralph Snodgrass /
  • Brian J. Underdown /

Current Share Structure

  • Market Cap: $22,788,102 - 05/18/2018
  • Authorized: 30,000,000 - 09/15/2015
  • Issue and Outstanding: 22,902,615 - 02/09/2018

 


Recent Filings from (NASDAQ: VTGN)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: September, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 14 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 09 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: July, 27 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: July, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 27 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: June, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 11 2018

 

 


Daily Technical Chart for (NASDAQ: VTGN)

Daily Technical Chart for (NASDAQ: VTGN)


Stay tuned for daily updates and more on (NASDAQ: VTGN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: VTGN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in VTGN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of VTGN and does not buy, sell, or trade any shares of VTGN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/